FRTX vs. NSTGQ, PALI, TTNP, CELZ, TCON, TCBP, KRBP, SRNE, FNCH, and ALBT
Should you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include NanoString Technologies (NSTGQ), Palisade Bio (PALI), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), TRACON Pharmaceuticals (TCON), TC Biopharm (TCBP), Kiromic BioPharma (KRBP), Sorrento Therapeutics (SRNE), Finch Therapeutics Group (FNCH), and Avalon GloboCare (ALBT). These companies are all part of the "biological products, except diagnostic" industry.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and NanoString Technologies (NASDAQ:NSTGQ) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to NanoString Technologies' net margin of -102.44%. NanoString Technologies' return on equity of 0.00% beat Fresh Tracks Therapeutics' return on equity.
In the previous week, Fresh Tracks Therapeutics' average media sentiment score of 0.00 equaled NanoString Technologies'average media sentiment score.
Fresh Tracks Therapeutics has higher earnings, but lower revenue than NanoString Technologies. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 76.8% of NanoString Technologies shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 3.1% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fresh Tracks Therapeutics and NanoString Technologies both received 0 outperform votes by MarketBeat users.
Summary
Fresh Tracks Therapeutics beats NanoString Technologies on 6 of the 11 factors compared between the two stocks.
Get Fresh Tracks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresh Tracks Therapeutics Competitors List
Related Companies and Tools
